Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598897 · ClinicalTrials.gov registry record · Phase 4
Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease
A Phase 4 study of Mycobacterium Avium Complex Lung Disease, sponsored by The University of Texas Health Science Center at Tyler.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT00598897: Completed Phase 4 study of Mycobacterium Avium Complex Lung Disease, sponsored by The University of Texas Health Science Center at Tyler.
NCT00598897 is a Phase 4 study of Mycobacterium Avium Complex Lung Disease that has completed, run by The University of Texas Health Science Center at Tyler. The registered enrollment target is 89 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00598897, a Phase 4 study of Mycobacterium Avium Complex Lung Disease, has completed, sponsored by The University of Texas Health Science Center at Tyler.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
Conditions Studied
Interventions
- DRUG clarithromycin, rifabutin
Study Locations (1)
Texas
- The University of Texas Health Science Center at Tyler - Tyler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 1995-08 |
| Est. Completion | 2017-05-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598897
The ClinicalTrials.gov registry entry for NCT00598897 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). The listed sponsor is The University of Texas Health Science Center at Tyler, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mycobacterium Avium Complex Lung Disease appearing as the primary indexed condition, and to 1 intervention - of which clarithromycin, rifabutin is the first listed.
NCT00598897 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00598897 about?
NCT00598897 is a clinical study titled "Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease". To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
What is the current status of trial NCT00598897?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 1995-08. Estimated completion is 2017-05-18.
What conditions does trial NCT00598897 study?
This clinical trial studies the following conditions: Mycobacterium Avium Complex Lung Disease.
What interventions are being tested in trial NCT00598897?
The interventions under investigation include: clarithromycin, rifabutin (DRUG).
Who is sponsoring clinical trial NCT00598897?
This trial is sponsored by The University of Texas Health Science Center at Tyler, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00598897 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.